

Divergent, Stereoselective Access to Heterocyclic α,α -Quaternary- and $\beta^{2,3,3}$ -Amino Acid Derivatives from a N-Pmp-protected Orn-Derived β -Lactam


Diego Núñez-Villanueva, M. Teresa García-López, Mercedes Martín-Martínez, Rosario González-Muñiz

Supporting Information


NMR Spectra.....	S2
------------------	----

¹H and ¹³C-NMR spectra.


¹H-NMR (300 MHz, CDCl₃). *N-p*-methoxyphenyl-Orn(*Z*)-OMe (5).





^{13}C -NMR (75 MHz, CDCl_3). *N*-*p*-methoxyphenyl-Orn(*Z*)-OMe (5).




¹H-NMR (300 MHz, CDCl₃). *N*-[(*S*)-2-Chloropropionyl]-*N*-Pmp-L-Orn(Z)-OMe (6).




¹³C-NMR (75 MHz, CDCl₃). *N*-[(*S*)-2-Chloropropionyl]-*N*-Pmp-L-Orn(*Z*)-OMe (6)




¹H-NMR (300 MHz, CDCl₃). (3*S*,4*S*)-4-[3'-(Benzyloxycarbonyl)amino]propyl-4-methoxycarbonyl-1-*p*-methoxyphenyl-3-methyl-2-oxoazetidine (7).




¹³C-NMR (75 MHz, CDCl₃). (3*S*,4*S*)-4-[3'-(Benzyloxycarbonyl)amino]propyl-4-methoxycarbonyl-1-*p*-methoxyphenyl-3-methyl-2-oxoazetidine (7).




¹H-NMR (300 MHz, CDCl₃). (3*S*,4*S*)-4-[3'-(Benzyloxycarbonyl)amino]propyl-4-methoxycarbonyl-3-methyl-2-oxoazetidine (8).




¹³C-NMR (75 MHz, CDCl₃). (3*S*,4*S*)-4-[3'-(Benzyloxycarbonyl)amino]propyl-4-methoxycarbonyl-3-methyl-2-oxoazetidine (8).




¹H-NMR (300 MHz, CDCl₃). (3*S*,4*S*)-4-[3'-(Benzyloxycarbonyl)amino]propyl-1-*tert*-butoxycarbonyl-4-methoxycarbonyl-3-methyl-2-oxoazetidine (9).




¹³C-NMR (75 MHz, CDCl₃). (3*S*,4*S*)-4-[3'-(Benzyloxycarbonyl)amino]propyl-1-*tert*-butoxycarbonyl-4-methoxycarbonyl-3-methyl-2-oxoazetidine (9).




¹H-NMR (300 MHz, CDCl₃). (3*S*,4*S*)-4-(*tert*-Butoxycarbonyl)amino-4-methoxycarbonyl-3-methyl-2-oxoazepane (10).




¹³C-NMR (75 MHz, CDCl₃). (3*S*,4*S*)-4-(*tert*-Butoxycarbonyl)amino-4-methoxycarbonyl-3-methyl-2-oxoazepane (10).




¹H-NMR (300 MHz, CDCl₃). (3*S*,4*S*)-1-*p*-Methoxyphenyl-1,6-diazaspiro[3.5]nonane-2,5-dione (11).




¹³C-NMR (75 MHz, CDCl₃). (3*S*,4*S*)-1-*p*-Methoxyphenyl-1,6-diazaspiro[3.5]nonane-2,5-dione (11).




¹H-NMR (300 MHz, CDCl₃). (3*S*,4*S*)-6-Benzyl-1-*p*-methoxyphenyl-1,6-diazaspiro[3.5]nonane-2,5-dione (12).




^{13}C -NMR (75 MHz, CDCl_3). (3*S*,4*S*)-6-Benzyl-1-*p*-methoxyphenyl-1,6-diazaspiro[3.5]nonane-2,5-dione (12).




¹H-NMR (300 MHz, CDCl₃). (3*S*,4*S*)-6-Benzyl-1,6-diazaspiro[3.5]nonane-2,5-dione (13).



¹³C-NMR (75 MHz, CDCl₃). (3*S*,4*S*)-6-Benzyl-1,6-diazaspiro[3.5]nonane-2,5-dione (13).



¹H-NMR (300 MHz, CDCl₃). Methyl (2*S*,3*S*)-3-*tert*-butoxycarbonylamino-2-methyl-3-(1'-benzyl-2'-oxopiperidin-3'-yl)propionate (14).



¹³C-NMR (75 MHz, CDCl₃). Methyl (2*S*,3*S*)-3-*tert*-butoxycarbonylamino-2-methyl-3-(1'-benzyl-2'-oxopiperidin-3'-yl)propionate (14).

